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INTRODUCTION
Platelet transfusion is used in patients w-ith a loxw platelet count
(thrombocytopenia or disordered platelet function who are
actively bleeding (therapeutic use) or who are at serious risk of
bleeding (prophy-lactic use). There is extensix-e clinical exidence
that platelet transfusions are x-aluable but the procedure also
carries risks and costs. The use of platelet transfusion has dexvel-
oped without much clinical trial-based exvidence on its effects and
complications or on the xvalue of additional procedures. such as
leucocyte depletion. This has obxvious implications for the ethi-
cally crucial questions of patient safety and the balance of risks
and costs to benefits. Despite the difficulties in performing
randomized clinical trials on an established procedure. the confer-
ence is firmlx of the iev that such studies are needed to allow
clearer. evidence-based guidelines for the use of platelet transfu-
sion to be formulated. Ex en when randomized trials are not
possible. the conference recommends that all decisions to trans-
fuse platelets should be made accordinc to written institutional
protocols that will allow generally applicable conclusions to be
drawn from the results.
INDICATIONS FOR PLATELET TRANSFUSION
Prophylactic
The main use of platelet transfusion is in the prevention of
bleeding in patients with haematolocical malignancies (particu-
larly leukaemias) who haxe bone marrow failure caused by their
disease or its treatment.
For patients wvith bone marrow failure. it has been accepted prac-
tice to transfuse platelets wihen levels are very low. Based on the
evidence presented at the meetinr. there was a general agreement
that a platelet threshold of 10 x I09 per litre is as safe as higher levels
for treatinc most patients without additional risk factors. These risk
factors. vihich include sepsis. concurrent use of drugs (e.gr. anti-
biotics) and other abnormalities ofhaemostasis. are indications for a
hirher threshold. Higher threshold numbers are also needed to coxer
inxasixe procedures. e.g. line insertions and biopsies. but there is no
consensus on appropriate thresholds. For uncomplicated patients.
exidence on the safety of ex en lo erplatelet thresholds than 10 x 103
per litre should be sought. Hoywexver. accurate countinc ofloy platelet
numbers may create difficulties vhen trying to reduce the threshold
belovi 10 x I0 per litre. In neonates. in whom there is a considerable
danger of haemorrhage. platelet transfusion is indicated at a higher
threshold than in adults.
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The avoidance of low haematocrit in patients w-ith thrombo-
c-topenia or disordered platelet function reduces the risk of
haemorrhage.
Therapeutic
Most major surgerv (includinc cardiac and vascular) can be
successfullv carried out without platelet transfusions. Patients who
have taken aspirin in the 10 days before surgery has-e increased
risk of bleedinc and the value of continuing, aspirin at this time
should be evaluated.
In massive haemorrhage. the first priorities are to achiex e
surgical haemostasis and resuscitation. There is a consensus to
transfuse platelets if the count is less than 50 x 109 per litre. but it
is clear that other clinical criteria need to be considered.
Liver transplantation gives special problems with haemostasis.
and platelet transfusion is frequently required. In lixer surgery.
thromboelastog,raphy has been show-n to be a good predictor of
platelet need and deserves exaluation in other areas. Anti-
fibrinolI-tic agyents have a platelet-sparing role in liver transplanta-
tion and complex cardiac surgical operations. They may also be
used in other situations. as may other agyents. such as DDAVP.
when platelet numbers or function are compromised.
Platelet transfusion is also used to treat clinically significant
bleeding in patients with idiopathic thrombocytopenic purpura
(FTP). The consensus view is that platelet transfusions have been
oxer-used in this area. especially in children. Intracranial or eve
haemorrhace or severe bleeding from the gut are the major
concerns. Except in these circumstances. platelet transfusion
should be avoided.
RISKS AND CONTRAINDICATIONS
The most common acute risk is bacterial infection. w-hich has been
under-reported. The important long-term risks oftransmitting Xiral
infection from the donor are w-ell recognized and have been
substantially reduced. However. the threat from new-ly recoanized
Xiruses is always present. In this connection the theoretical possi-
bility that blood products may be able to transmit the agent of
variant Creutzfeldt-Jakob disease (CJD) has attracted attention
and cannot be discounted. Experimental procedures for reducingy
the risk of transmitting bacterial and viral infection bv chemical
treatment of the platelet preparations (e.g. by Psoralens plus ultra-
violet lirht) are under investigation.
The presence of w-hite blood cells in the platelet preparation
enhances the risk of certain viral infections and is largely respon-
sible for cenerating cvtokines. which can ixve rise to febrile
reactions after platelet transfusion. Platelet transfusion through
negatively charged filters can also activate the contact system and
gix e rise to significant hypotension in patients receiving
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angiotensin-cons esting enzvme (ACE) inhibitors. A tenfold
reduction in white cell numbers (leucoreduction) before storage of
platelets is sufficient to abolish most febrile reactions and is
readilI achievable in both buff) coat-derived and apheresis
platelets. White cell numbers can be further reduced to less than
5 x 106 per dose (leucodepletion) by specialized manufacture. by
improving the apheresis technique and by pre-storage filtration.
Leucodepleted platelets reduce transmission of some viruses and
febrile reactions. as well as reducina HLA allo-immunization.
which can cause patients to become refractory (resistant) to further
platelet transfusions.
Irradiation ofplatelet concentrates is required to prevent graft Xs
host disease. and this needs to follow national auidelines.
Platelet transfusion is contraindicated in heparin-induced
thrombocytopenia. thrombotic thrombocytopenic purpura and the
haemolyItic uraemic syndrome.
RECIPIENTS WHO ARE REFRACTORY TO
PLATELET TRANSFUSIONS
Failure to achieve a satisfactorv response to platelet transfusion
(refractonrness) occurs in up to halfofthose receivnig prophylactic
transfusions. This is defined by the poor increment in platelet
count rather than on clinical grounds. Patients who remain refrac-
tory for immunological reasons. often receive prophylactic trans-
fusions with HLA-matched or crossmatch-compatible platelets.
Satisfactors increments are frequently obtained by these
approaches. but their effectiveness in reducing sexere bleeding
deserves more detailed evaluation. This also applies to the relatixe
effectiveness of HLA matching compared with platelet cross-
matching. and whether patients who remain refractory despite
these measures should only be transfused therapeutically.
QUALITY CONTROL OF PLATELET
PREPARATIONS
Further quality control measures should become routine in addi-
tion to those alreadv undertaken and should include more accurate
measurements of low white cells and high platelet counts. micro-
biological safetv as well as rapid techniques for detectinc *-iral
nucleic acid in platelet preparations. There are few appropriate
surrogate markers that are relevant to the arrest or prevention of
bleeding in patients. although the swirl test has its adherents.
Performance in quality assurance should meet evolving national
standards.
CONCLUSION
The overall conclusion is that platelet transfusion is a x-ell-
established clinical procedure. but it can never be entirely safe and
must be given onlyx hen there is clear clinical justification.
Nevertheless. the precise indications for its use and the optimal
specification of the product still need to be defined. These goals
will be achieved only by a combination ofprospectix e randomized
trials with the information that will come from the use of clearly
defined protocols and their efficient audit.
British Joumal ofCancer (1998) 78(3), 290-291 0 Cancer Research Campaign 1998